Vera Therapeutics, Inc. (VERA) Q3 2025 10-Q Quarterly Report
Vera Therapeutics, Inc. (VERA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Vera Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • No newly added risk factor this quarter; risks consistent with prior 10-K filing
- • Material update on financing: $497.4M cash and marketable securities as of Sept 30, 2025, sufficient to fund operations beyond 12 months but capital needs remain high
Vera Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$80M
▼ -72.2% YoY▼ -4.9% QoQ
ROE
-20.1%
Total Assets
$518M
EPS (Diluted)
$-1.26
▼ -46.5% YoY▼ -5.0% QoQ
Operating Cash Flow
-$62M
▼ -67.8% YoY▼ -13.0% QoQ
Source: XBRL data from Vera Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vera Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.